This segment focuses on the research, development, and clinical trials of oral therapeutics for the treatment of Inflammatory Bowel Diseases (IBD), including Ulcerative Colitis (UC) and Crohn's Disease (CD). The primary focus is on BT-11, an oral lanthionine synthetase C-like protein 2 (LANCL2) agonist, and NX-13, a gut-restricted oral therapeutic targeting NOD-like receptor X1. Research and development activities include preclinical studies, Phase 2 clinical trials, and the evaluation of patient-derived organoid models. The technologies employed involve small molecule drug discovery and development, with a focus on modulating the immune response within the gastrointestinal tract. The patient impact is significant, aiming to provide safer and more effective treatments for individuals suffering from debilitating IBD symptoms. Market positioning is enhanced by the potential for first-in-class oral therapies, offering a competitive advantage over existing treatments. Future opportunities include expanding the clinical development of BT-11 and NX-13, and exploring combination therapies. Regulatory and clinical aspects involve navigating FDA approval processes and conducting rigorous clinical trials to demonstrate efficacy and safety. This segment is now part of AbbVie's portfolio following the acquisition, which provides access to resources and expertise to accelerate the development and commercialization of these therapies.

This segment is dedicated to the research and development of PX-69, an oral PLXDC2 agonist, for the treatment of diabetic nephropathy and rheumatoid arthritis. The research and development activities include preclinical studies, formulation development, and clinical trial planning. The technologies and methodologies used involve small molecule drug discovery and development, with a focus on targeting specific pathways involved in the progression of these diseases. The therapeutic areas covered are diabetic nephropathy and rheumatoid arthritis, aiming to address the unmet medical needs of patients suffering from these conditions. The patient impact is focused on improving kidney function in diabetic nephropathy and reducing inflammation and joint damage in rheumatoid arthritis. Market positioning is based on the potential for novel oral therapies that offer improved efficacy and safety profiles compared to existing treatments. Future opportunities include advancing PX-69 through clinical trials and exploring potential combination therapies. Regulatory and clinical aspects involve obtaining FDA approval and conducting clinical trials to demonstrate the safety and efficacy of PX-69. This segment is now part of AbbVie's portfolio following the acquisition, which provides access to resources and expertise to accelerate the development and commercialization of these therapies.